Objective-Tissue kallikrein, a widely used vasodilator for the treatment of hypertension and peripheral circulatory disorder, acts by releasing kinin, a potent vasodilator peptide. To identify the role of tissue kallikrein in retinal neovascularization, we investigated the antiangiogenic effect by using an in vitro and in vivo angiogenesis model. Methods and Results-Tissue kallikrein in vitreous fluid was markedly elevated in proliferative diabetic retinopathy patients compared with that in control patients with macular hole and epiretinal membrane. Tissue kallikrein inhibited vascular endothelial growth factor-165 (VEGF 165 )-induced tube formation, proliferation, and migration in vitro angiogenesis model via suppression of the VEGF 165 -induced phosphorylation of VEGF receptor-2. Furthermore, tissue kallikrein cleavage of VEGF 165 was on the C-terminal side, which was analyzed by Western blotting and mass spectrometry. When administered subcutaneously, tissue kallikrein reduced the pathological vascular changes in retinal neovascularization induced in neonatal mice by returning the retina to normoxia after exposure to hyperoxia. Conclusion-These findings indicate that tissue kallikrein is partly involved in pathogenesis of proliferative diabetic retinopathy and may be a promising therapeutic agent that could cleave VEGF 165 itself when administered by a peripheral route. (Arterioscler Thromb Vasc Biol. 2011;31:1041-1048.)
I rreversible vision loss and blindness has been increasing because of abnormal retinal neovascularization. Retinal neovascular diseases, including diabetic retinopathy, agerelated macular degeneration, and retinopathy of prematurity, are the major causes of blindness worldwide. [1] [2] [3] Especially in the advanced countries, lifestyle changes and superaging have led to a rapid rise in the number of cases of diabetic retinopathy and age-related macular degeneration.
An extensive proliferation of new blood vessels in the retina is induced by a specific cytokine, vascular endothelial growth factor (VEGF). 4, 5 Recently, intravitreal injection of an anti-VEGF antibody, a VEGF aptamer, and a VEGF Fab fragment has been used in the treatment of age-related macular degeneration, proliferative diabetic retinopathy (PDR), central retinal vein occlusion, and neovascular glaucoma. 6 -9 However, repeated injections are associated with potential risks of vitreous hemorrhages, retinal detachment, and decrease in compliance. 10, 11 Therefore, noninvasive delivery systems, such as peripheral administration, are required.
The kallikrein-kinin system is present in various vascular territories in both humans and mice. [12] [13] [14] Tissue kallikrein endogenously forms kinins, such as bradykinin, which can participate in the regulation of vascular tone. [15] [16] [17] Tissue kallikrein has been demonstrated to improve choroidal and retinal circulatory disorders in the renal hypertensive model 18 and in ischemic injury induced by endothelin-1, 19 one of the most potent endogenous vasoconstrictors. 20 We have recently reported that tissue kallikrein administered intravenously normalizes retinal vasopermeability via suppression of the intraocular VEGF level in streptozotocin-induced diabetic rats. 21 These reports have indicated that improvement of blood flow by tissue kallikrein may have a potential clinical role in preventing retinal neovascularization. Because tissue kallikrein is used clinically as an orally administered vasodilator for improvement of chorioretinal blood flow, it may affect retinal neovascularization in diabetic retinopathy. However, to our knowledge, no studies have yet reported a role for tissue kallikrein in the pathogenesis of diabetic retinopathy, an antiangiogenic effect of tissue kallikrein, or the underlying mechanism.
On the basis of the available reports, we measured VEGF and tissue kallikrein in vitreous fluid from patients with PDR to define the relationship between VEGF and tissue kallikrein. Next, we investigated the effects of tissue kallikrein on VEGF 165 -induced angiogenesis and observed not only the effects of tissue kallikrein against the VEGF 165 signaling pathway using human umbilical vein endothelial cells (HU-VECs) and human retinal microvascular endothelial cells (HRMECs) but also the cleaving action of tissue kallikrein on VEGF 165 itself. We also evaluated the antiangiogenic effect of tissue kallikrein by peripheral administration in a murine oxygen-induced retinopathy (OIR) model.
Methods
An expanded Methods section is available in Supplemental Data I, available online at http://atvb.ahajournals.org.
Preparation of Vitreous Fluid Samples
This study was conducted according to the tenets of the Declaration of Helsinki and was carried out after approval was received from the institutional review committee of Osaka Medical College. Informed consent was obtained from all patients after an explanation of the purpose and procedures of the study.
Vitreous samples were collected from 97 eyes undergoing pars plana vitrectomy for the treatment of diabetic retinopathy and other retinal disorders at Osaka Medical College Hospital. Undiluted vitreous samples were collected from 97 eyes of 97 individuals with macular hole (MH; 40 eyes), epiretinal membrane (ERM; 20 eyes), and PDR (37 eyes). Two samples were obtained from each eye during a repeat vitrectomy, and samples with obvious bleeding were excluded. None of the patients with an idiopathic MH was affected by diabetes. Details of the patients are shown in the Table.
OIR Model in Mice
The OIR model was produced as previously described. 22 At postnatal day 7 (P7), mice and their mothers were placed in a custom-built chamber and exposed to an atmosphere of 75Ϯ1% oxygen for 5 days, at a temperature of 24Ϯ2°C. Oxygen was continuously monitored with an oxygen controller (PRO-OX 110, Reming Bioinstruments Co., Redfield, SD). On P12, animals were returned to room air (21% O 2 ) until P17. The tissue kallikrein was given subcutaneously at 20 or 50 g/kg once a day immediately after hyperoxia (P12) until P16.
Results

Elevated Tissue Kallikrein and VEGF Concentrations in Vitreous Fluids From PDR Patients
We measured the concentrations of tissue kallikrein and VEGF in vitreous fluids obtained from patients with PDR and other diseases. The concentration of tissue kallikrein was significantly higher in PDR patients (meanϮSEM, 93 821.2Ϯ12 192.3 pg/ mL, nϭ37) than in other patients (MH, 15 698.8Ϯ3131.4 pg/mL, nϭ40; ERM, 20 625.7Ϯ3367.9 pg/mL, nϭ20) ( Figure  1A and 1B). Concentrations of VEGF were also higher in PDR patients (787.1Ϯ208.4 pg/mL, nϭ37, versus MH; 4.7Ϯ1.1 pg/mL, nϭ40, ERM; 0.1Ϯ0.1 pg/mL, nϭ20 [ Figure 1C ]). The correlation between concentrations of tissue kallikrein and VEGF in vitreous fluids of all patients was significantly positive (Spearman ϭ0.494, PϽ0.0001 [ Figure 1D ]).
VEGF 165 -Induced Tube Formation, Cell Proliferation, and Migration Were Suppressed by Tissue Kallikrein
HUVECs became organized into complex tubular networks in response to VEGF 165 (10 ng/mL), and this effect was concentration-dependently suppressed by tissue kallikrein (Figure 2A ). Tissue kallikrein (0.01 to 10 g/mL) concentration-dependently inhibited tube formation and significantly inhibited tube area when supplied at 1 and 10 g/mL ( Figure 2B ). It also reduced length, joints, and paths when supplied at 0.1 to 10 g/mL ( Figure 2C to 2E).
Cell proliferation in HRMECs was increased to 1.5 times the rate in control cells by VEGF 165 (10 ng/mL) treatment ( Figure  2F ). Tissue kallikrein inhibited this proliferation: its effect was significant at 10 g/mL. On the other hand, tissue kallikrein alone had little effect on basal proliferation ( Figure 2F ). Tissue kallikrein also inhibited the VEGF 165 -induced migration at 1 and 10 g/mL in HRMECs ( Figure 2G and 2H).
Tissue Kallikrein Suppressed VEGF 165 -Induced Phosphorylation of VEGF Receptor-2, ERK1/2, and p38 Mitogen-Activated Protein Kinase
The phosphorylation of extracelluar signal-regulated kinase 1/2 (ERK1/2) and the phosphorylation of p38 mitogen-activated protein kinase (p38MAPK) are important signaling events for the proliferation and migration of endothelial cells following induction by VEGF. Therefore, we examined the effects of tissue kallikrein on the VEGF 165 -induced phosphorylation of ERK1/2 and p38MAPK in HUVECs. Tissue kallikrein at 10 g/mL significantly suppressed VEGF 165induced ERK1/2 and p38MAPK phosphorylation ( Figure 3A ).
We next investigated the action of tissue kallikrein on VEGF receptor-2 (VEGFR-2) in the uppermost stream of VEGF 165 signaling by examining the effect of tissue kallikrein on the VEGF 165 -induced VEGFR phosphorylation in HUVECs. VEGF 165 (10 ng/mL) increased the phosphorylation of VEGFR, and tissue kallikrein at 1 and 10 g/mL significantly inhibited this increase in both HUVECs and HRMECs ( Figure 3B and 3C).
Tissue Kallikrein Cleaved VEGF 165
Tissue kallikrein cleaved VEGF 165 , as confirmed by immunoblot analysis with 2 kinds of anti-VEGF antibodies (N-terminal and C-terminal) ( Figure 4A ). The VEGF 165 product, following cleavage by tissue kallikrein, could be bound to an anti-N-terminal VEGF antibody but not to an anti-C-terminal VEGF antibody (Figure 4Aa and 4Ab). These results indicate that tissue kallikrein cleaves VEGF 165 at the C terminus. Cleavage by tissue kallikrein was concentration dependent. When tissue kallikrein was supplied at 1 g/mL, intact VEGF 165 could still be clearly resolved, whereas at 10 g/mL, cleaved VEGF 165 was clearly detected ( Figure 4A ). Tissue kallikrein at 10 g/mL decomposed VEGF 165 in a time-dependent manner ( Figure 4B ). In the vitreous fluids of both MH and PDR patients, the cleaved form of VEGF 165 was not detected ( Figure 4C ). When tissue kallikrein was supplied (at a final concentration of 10 g/mL), the cleaved form of the VEGF 165 was detected ( Figure 4C ). The cleaved VEGF 165 protein was digested with Lys-C to yield peptides that have amino groups at both ends and a C-terminal peptide that has only an ␣-amino group. Fragments of C-terminal peptides were not observed ( Figure  4Da ). From this result, it was supposed that the C-terminal amino acid of the cleaved VEGF 165 was a Lys. Mass spectrometry after the Lys-C digestion showed the C-terminal peptides to be CECRPK (iodoacetamide-CECRPK; m/z 849) ( Figure 4Db ). Theoretical fragments on the C-terminal side were not otherwise observed. On the other hand, although a peak of MSFLQHNKCE (iodoacetamide-MSFLQHNKCE; m/z 1293) was observed following Glu-C digestion, theoretical fragments on the C-terminal side were not detected, as for Lys-C digestion (Figure 4Dc ). These results indicate that the C-terminal amino acid residue of VEGF 165 cleaved by tissue kallikrein is Lys (Lys107, Lys108, or both) ( Figure 4E ).
Tissue Kallikrein Inhibited Retinal Neovascularization in a Murine OIR Model
The effect of tissue kallikrein on retinal neovascularization in vivo was evaluated using an OIR model. Tissue kallikrein significantly decreased the retinal neovascularization compared with vehicle treatment, which was observed as abnormal retinal vessel formation by fluorescein conjugated dextran (Figure 5Aa , 5Ac, 5Ae, 5Ag, and 5Ai). The node regions (represented by green labels in the analyzed image) were decreased by tissue kallikrein treatment (versus vehicle) (Figure 5Ab , 5Ad, 5Af, 5Ah, and 5Aj). The tissue kallikrein-treated group was significantly suppressed (versus vehicle) in both the number of nodes and the nodes area in a dose-dependent manner ( Figure 5B and 5C). Side effects of tissue kallikrein were checked in normal retinal vessels by measuring the capillary-free area, which was caused by centering on optic nerve (Figure 5Db and 5Dc) . Revascularization of the capillary-free area did not differ between vehicle and tissue kallikrein treatments ( Figure 5E ). In tissue kallikrein-treated group, we detected cleaved VEGF 164 and a decrease in VEGF 164 ( Figure 5F ).
Discussion
In the present study, we confirmed that the vitreous concentrations of tissue kallikrein and VEGF were higher in PDR patients than in control patients with MH and ERM. We also found a positive correlation between tissue kallikrein and VEGF (in the entire patient contingent). Tissue kallikrein inhibited VEGF 165 -induced tube formation, proliferation, and migration in our in vitro model and also cleaved VEGF 165 . In the in vivo study, the systemic administration of tissue kallikrein inhibited the formation of abnormal retinal vessels in OIR model mice without affecting normal vessels. To elucidate the correlation of tissue kallikrein and VEGF, we measured their concentrations in the vitreous fluids of patients with PDR, MH, and ERM. Tissue kallikrein was not only significantly higher in PDR patients than the control patients, but tissue kallikrein and VEGF also showed a positive correlation with each other These findings indicate that an increase in tissue kallikrein might prevent the abnormal increase in VEGF in PDR patients and therefore might be efficacious for retinal neovascularization.
In the present in vitro study, tissue kallikrein at 0.1 to 10 g/mL inhibited VEGF 165 -induced tube formation (tube length, joints, and paths) and both VEGF 165 -induced proliferation and migration in HUVECs (Supplemental Figure I) and HRMECs. These data indicate that tissue kallikrein inhibits VEGF 165induced tube formation through the suppression of both proliferation and migration of endothelial cells.
The VEGF 165 -induced phosphorylation of ERK1/2, an important factor involved in VEGF 165 -induced endothelial cell proliferation, 23 is also inhibited in the presence of bradykinin. 24 In a HRMEC proliferation test, a dual antagonist of bradykinin B 1 and B 2 had no effect on the antiproliferative activity of tissue kallikrein (Supplemental Figure II) , indicating that tissue kallikrein might suppress the VEGF 165induced proliferation independently of bradykinin receptors.
Next, we studied the mechanism of antiangiogenic effect of tissue kallikrein using immunoblot analyses for VEGF signaling. VEGF signaling includes both ERK1/2 and p38MAPK, which are primarily involved in cell proliferation and migration. 23, [25] [26] [27] In the present study, tissue kallikrein inhibited VEGF 165 -induced angiogenesis by suppression of cell proliferation and migration; its mechanism might be due to inhibition of the ERK1/2 and p38MAPK pathways via inhibition of the phosphorylation of VEGFR-2, which exists in the uppermost stream of VEGF signaling.
To clarify the mechanism of antiangiogenic effects of tissue kallikrein, we investigated whether tissue kallikrein has a direct action on VEGF 165 because tissue kallikrein did not proteolyze VEGFR (Supplemental Figure III) . VEGF 165 exists at high frequency, and its physiological activity is high compared with other isoforms. 28 -30 Although tissue kallikrein cleaves Met-Lys and Arg-Ser bonds in kininogen, 31 we identified that VEGF 165 was interestingly cleaved at its C terminus (Lys107, Lys108, or both) by tissue kallikrein. The heparin binding function of VEGF 165 reportedly is completely mediated by the C-terminal domain. (111-165). 32 Therefore, the cleaved VEGF 165 product cut by tissue kallikrein appeared to lose almost all of the bioactivity for VEGFR-2. In the present experiments, tissue kallikrein at 10 g/mL inhibited VEGF 165 -induced proliferation and migration; thus, the cleavage effect of tissue kallikrein at 0.1 to 10 g/mL for VEGF 165 (10 ng/mL) was consistent with the concentrations (0.1 to 10 g/mL) in our in vitro studies (VEGF 165 -induced tube formation, proliferation, and migration). These concentrations in both the tube formation and the cleavage assay were consistent with those in the human vitreous with PDR. These findings indicate that tissue kallikrein at 100 ng/mL (a concentration in the human vitreous) might have an antiangiogenic effect via the degradation of VEGF 165 .
We investigated the antiangiogenic effect of peripherally administered tissue kallikrein on retinal neovascularization using OIR model mice as an in vivo model. The systemic administration of tissue kallikrein inhibited retinal neovascularization, although tissue kallikrein had no influence on the size of the capillary-free area (an index of retinal revascularization), on behavior, or on body weight. We confirmed that tissue kallikrein reduced the expression of VEGF 164 (termed VEGF 165 in humans) in the retina of the OIR model mice. Similar to the in vitro study, tissue kallikrein at a concentration that inhibits retinal neovascularization in the OIR model might decompose. In a tissue kallikrein-treated group, the cleaved form of the VEGF 164 and a decrease in VEGF 164 were detected. The data indicate that tissue kallikrein inhibited retinal neovascularization via the cleavage of VEGF 164 . We have reported that tissue kallikrein decreased the expression of VEGF 164 by upregulating the production of nitric oxide. 21 Taken together, these data suggested that tissue kallikrein might inhibit retinal neovascularization via the dual action of both cleaving the VEGF 164 and decreasing the expression of VEGF in the OIR model.
In newborn mouse pups, the primary vascular network had reached the periphery by approximately P8. 33 At the termination of the experiment (P8), there were no statistically significant differences in any parameters (tube area, length, joints, and paths) between control and the tissue kallikrein treatment (at a dosage of 50 g/kg) (Supplemental Figure  IV) . These data strongly suggested that tissue kallikrein did not inhibit retinal physiological angiogenesis. Retinal physiological vascular development required VEGF 121 (termed VEGF 120 in the mouse), whereas VEGF 165 (termed VEGF 164 in the mouse) was deeply involved in retinal pathological angiogenesis. 34, 35 Tissue kallikrein did not inhibit either proliferation or migration induced by VEGF 121 (Supplemental Figure VA and VB). Tissue kallikrein had no effect on the activity of VEGF 121 (Supplemental Figure VC) . For selective cleavage of VEGF 165 , tissue kallikrein might increase to maintain homeostasis in human vitreous fluids.
In conclusion, tissue kallikrein might be partly involved in the pathogenesis of PDR, and it may have an antiangiogenic effect through the cleavage of VEGF 165 selectively when administered by a peripheral route. Our findings indicate the clinical possibilities of tissue kallikrein application to be as follows: (1) the antiangiogenic mechanism of tissue kallikrein is different from the remedies used in the retinal neovascularization, and (2) the administration route is peripheral, with a low risk of side effects and a high compliance compared with therapeutic methods using intravitreal administration. Although tissue kallikrein has been used clinically as an oral agent for 22 years, no side effects, such as inhibiting normal neovascularization, have been reported at all. Therefore, tissue kallikrein may be a promising therapeutic agent for retinal neovascularization or hyperpermeability in patients with PDR, age-related macular degeneration, central retinal vein occlusion, and neovascular glaucoma.
